

Edgar Filing: ATRIX LABORATORIES INC - Form 8-K

ATRIX LABORATORIES INC
Form 8-K
April 24, 2001

1

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

April 20, 2001

(Date of earliest event reported)

ATRIX LABORATORIES, INC.

(Exact name of Registrant as specified in its charter)

Delaware

0-18231

84-1043826

(State or Other Jurisdiction
of Incorporation)

(Commission File No.)

(IRS Employer Identification No.)

2579 Midpoint Drive, Fort Collins, Colorado 80525

(Address of principal executive offices, including zip code)

(970) 482-5868

(Registrant's telephone number, including area code)

2

Item 5. Other Events.

Atrix Laboratories, Inc. (the "Company") announced today that it has settled the first of three licensing disputes with Block Drug, a wholly owned subsidiary of GlaxoSmithKline submitted last year. The settlement resolves a

Edgar Filing: ATRIX LABORATORIES INC - Form 8-K

pricing dispute over Block's sale of the Company's periodontal product, Atridox(R) and provides payment owed to the Company for the sale of the product. As part of the settlement, the Company received payment owed for product sales in 1999. In addition, the Company implemented a new pricing schedule for future purchases in an effort to resolve issues of this type in the future. The Company intends to pursue resolution of the remaining legal issues with Block, including Block's failure to pay the Company certain milestones following approval by the U.S. Food and Drug Administration of Atrisorb-D(R) guided tissue regeneration barrier product.

The text of Press Release is attached hereto as Exhibit 99.1.

Item 7. Exhibits.

99.1 Text of Press Release dated April 24, 2001.

3

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATRIX LABORATORIES, INC.

By: /s/ Brian G. Richmond

Brian G. Richmond
Chief Financial Officer

Date: April 24, 2001

4

EXHIBIT INDEX

Exhibit	Description
-----	-----
99.1	Text of Press Release dated April 24, 2001.